PMCB
PharmaCyte Biotech, Inc.
Price Chart
Latest Quote
$0.72
-0.06 (-8.16%)
Current Price
| Previous Close | $0.78 |
| Open | $0.78 |
| Day High | $0.80 |
| Day Low | $0.72 |
| Volume | 205,490 |
Stock Information
| Shares Outstanding | 10.74M |
| Cash Equivalents | $20.54M |
| Net Income | $-7.49M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $7.71M |
| EPS (TTM) | $-0.85 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-11.96M |
| Income | $-7.49M |
| Book/sh | $3.59 |
| Cash/sh | $1.91 |
| Employees | 2 |
Financial Ratios
| Quick Ratio | 12.24 |
| Current Ratio | 12.33 |
Returns & Margins
| ROA | -6.75% |
| ROE | -8.24% |
Ownership
| Insider Ownership | 5.74% |
| Institutional Ownership | 9.01% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -1.89 |
| P/B | 0.20 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $0.77 |
| SMA50 | $0.76 |
| SMA200 | $0.83 |
| RSI | 34.35 |
| ATR | 0.0535 |
| Shares Float | 9.96M |
| Short Float | 3.71% |
| Short Ratio | 1.25 |
| Volatility | 0.52 |
| Rel Volume | 1.20 |
Performance History
| Week | -4.31% |
| Month | -1.94% |
| Quarter | +2.25% |
| 6 Months | -24.44% |
| YTD | -2.74% |
| Year | -32.28% |
| 3 Years | -76.92% |
| 5 Years | -96.46% |
| 10 Years | -99.23% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $0.72 | 205,300 |
| 2026-06-17 | $0.79 | 77,700 |
| 2026-06-16 | $0.83 | 151,000 |
| 2026-06-15 | $0.81 | 133,300 |
| 2026-06-12 | $0.76 | 170,300 |
| 2026-06-11 | $0.75 | 191,000 |
| 2026-06-10 | $0.70 | 32,400 |
| 2026-06-09 | $0.70 | 63,300 |
| 2026-06-08 | $0.70 | 236,400 |
| 2026-06-05 | $0.70 | 196,400 |
| 2026-06-04 | $0.73 | 52,900 |
| 2026-06-03 | $0.73 | 86,300 |
| 2026-06-02 | $0.75 | 129,800 |
| 2026-06-01 | $0.80 | 90,400 |
| 2026-05-29 | $0.83 | 146,800 |
| 2026-05-28 | $0.86 | 412,100 |
| 2026-05-27 | $0.76 | 79,000 |
| 2026-05-26 | $0.79 | 125,300 |
| 2026-05-22 | $0.81 | 573,100 |
| 2026-05-21 | $0.80 | 263,200 |
| 2026-05-20 | $0.77 | 238,100 |
| 2026-05-19 | $0.73 | 210,400 |
About PharmaCyte Biotech, Inc.
PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company's cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. It also develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; license agreements with SG Austria Pte. Ltd.; and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-04-30 | 2024-04-30 | 2023-04-30 | 2022-04-30 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $4,377,862 | $6,520,008 | $6,455,494 | $4,392,014 |
| Other Income Expense | $33,618,351 | $3,454,952 | $202,002 | $-4,283 |
| Other Non Operating Income Expenses | $-965 | $191,145 | $202,002 | $-4,283 |
| Net Non Operating Interest Income Expense | $1,415,561 | $3,398,819 | $1,937,499 | $157,136 |
| Operating Expense | $4,377,862 | $6,520,008 | $6,455,494 | $4,392,014 |
| General And Administrative Expense | $3,939,446 | $6,112,577 | $4,752,002 | $2,156,326 |
| Other Operating Expenses | - | $1,322,414 | $1,234,956 | $1,544,751 |
| Interest Expense | - | - | $0 | $509 |
| Interest Expense Non Operating | - | - | $0 | $509 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $30,656,050 | $333,763 | $-4,315,993 | $-4,239,161 |
| Net Interest Income | $1,415,561 | $3,398,819 | $1,937,499 | $157,136 |
| Interest Income | $1,415,561 | $3,398,819 | $1,937,499 | $157,645 |
| Normalized Income | $4,096,790 | $-2,244,645 | $-4,315,993 | $-4,239,161 |
| Net Income From Continuing And Discontinued Operation | $30,656,050 | $333,763 | $-4,315,993 | $-4,239,161 |
| Total Operating Income As Reported | $-4,377,862 | $-8,520,008 | $-6,455,494 | $-4,392,014 |
| Net Income Common Stockholders | $23,362,107 | $-17,237,403 | $-4,315,993 | $-4,239,161 |
| Net Income | $30,656,050 | $333,763 | $-4,315,993 | $-4,239,161 |
| Net Income Including Noncontrolling Interests | $30,656,050 | $333,763 | $-4,315,993 | $-4,239,161 |
| Net Income Continuous Operations | $30,656,050 | $333,763 | $-4,315,993 | $-4,239,161 |
| Pretax Income | $30,656,050 | $333,763 | $-4,315,993 | $-4,239,161 |
| Special Income Charges | $-2,019,000 | $-3,572,193 | $0 | $0 |
| Interest Income Non Operating | $1,415,561 | $3,398,819 | $1,937,499 | $157,645 |
| Operating Income | $-4,377,862 | $-6,520,008 | $-6,455,494 | $-4,392,014 |
| Per Share | ||||
| Diluted EPS | $3.19 | $-1.80 | $-0.22 | $-0.27 |
| Basic EPS | $3.19 | $-1.80 | $-0.22 | $-0.27 |
| Other | ||||
| Tax Effect Of Unusual Items | $7,060,056 | $685,399 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-37,997,178 | $-9,783,815 | $-6,455,494 | $-4,238,652 |
| Total Unusual Items | $33,619,316 | $3,263,807 | $0 | $0 |
| Total Unusual Items Excluding Goodwill | $33,619,316 | $3,263,807 | $0 | $0 |
| EBITDA (Bullshit earnings) | $-4,377,862 | $-6,520,008 | $-6,455,494 | $-4,238,652 |
| EBIT | $-4,377,862 | $-6,520,008 | $-6,455,494 | $-4,238,652 |
| Diluted Average Shares | $7,329,596 | $9,581,059 | $19,489,204 | $15,521,654 |
| Basic Average Shares | $7,329,596 | $9,581,059 | $19,489,204 | $15,521,654 |
| Diluted NI Availto Com Stockholders | $23,362,107 | $-17,237,403 | $-4,315,993 | $-4,239,161 |
| Otherunder Preferred Stock Dividend | $6,164,184 | $15,053,521 | $0 | - |
| Preferred Stock Dividends | $1,129,759 | $2,517,645 | - | - |
| Gain On Sale Of Ppe | $0 | $-1,572,193 | $0 | - |
| Other Special Charges | $2,019,000 | - | - | - |
| Impairment Of Capital Assets | $0 | $2,000,000 | $0 | - |
| Gain On Sale Of Security | $35,638,316 | $6,836,000 | - | - |
| Research And Development | $438,416 | $407,431 | $468,536 | $690,937 |
| Selling General And Administration | $3,939,446 | $6,112,577 | $4,752,002 | $2,156,326 |
| Other Gand A | $3,939,446 | $6,112,577 | $3,800,655 | $1,899,836 |
| Write Off | - | $1,572,193 | $0 | - |
| Salaries And Wages | - | $1,141,215 | $951,347 | $256,490 |
Fetched: 2026-06-18
Balance Sheet (Annual)
| Metric | 2025-04-30 | 2024-04-30 | 2023-04-30 | 2022-04-30 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $50,341,642 | $37,965,192 | $69,140,917 | $86,370,339 |
| Total Assets | $55,168,353 | $59,903,883 | $73,276,925 | $90,624,136 |
| Total Non Current Assets | $32,793,115 | $9,464,115 | $5,129,308 | $5,129,308 |
| Other Non Current Assets | $7,688 | $7,688 | $7,688 | $7,688 |
| Non Current Note Receivables | $0 | $2,755,000 | $0 | - |
| Financial Assets | $8,762,000 | $5,152,000 | $0 | - |
| Goodwill And Other Intangible Assets | $1,549,427 | $1,549,427 | $3,549,427 | $3,549,427 |
| Other Intangible Assets | $1,549,427 | $1,549,427 | $3,549,427 | $3,549,427 |
| Current Assets | $22,375,238 | $50,439,768 | $68,147,617 | $85,494,828 |
| Other Current Assets | $223,759 | $259,800 | $107,681 | - |
| Hedging Assets Current | $2,917,000 | $0 | - | - |
| Receivables | $3,696,000 | $0 | - | - |
| Notes Receivable | $3,696,000 | $0 | - | - |
| Cash Cash Equivalents And Short Term Investments | $15,538,479 | $50,179,968 | $68,039,936 | $85,400,656 |
| Cash And Cash Equivalents | $15,172,163 | $50,179,968 | $68,039,936 | $85,400,656 |
| Prepaid Assets | - | - | $107,681 | $94,172 |
| Cash Financial | - | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $3,277,284 | $20,389,264 | $586,581 | $704,370 |
| Total Non Current Liabilities Net Minority Interest | $363,000 | $12,968,000 | $0 | $0 |
| Derivative Product Liabilities | $338,000 | $12,968,000 | $0 | - |
| Current Liabilities | $2,914,284 | $7,421,264 | $586,581 | $704,370 |
| Payables And Accrued Expenses | $2,914,284 | $1,124,568 | $586,581 | $704,371 |
| Payables | $424,628 | $729,441 | $186,377 | $205,361 |
| Total Tax Payable | $25,424 | $340,072 | $58,096 | - |
| Accounts Payable | $399,204 | $389,369 | $128,281 | $205,361 |
| Other Current Liabilities | - | $6,296,696 | - | $-1 |
| Equity | ||||
| Common Stock Equity | $51,891,069 | $27,647,603 | $72,690,344 | $89,919,766 |
| Total Equity Gross Minority Interest | $51,891,069 | $39,514,619 | $72,690,344 | $89,919,766 |
| Stockholders Equity | $51,891,069 | $39,514,619 | $72,690,344 | $89,919,766 |
| Gains Losses Not Affecting Retained Earnings | $-23,869 | $-23,511 | $-23,003 | $-15,757 |
| Other Equity Adjustments | $-23,869 | $-23,511 | $-23,003 | $-15,757 |
| Retained Earnings | $-84,968,960 | $-115,625,010 | $-115,958,773 | $-111,648,656 |
| Preferred Stock Equity | - | $11,867,016 | - | - |
| Other | ||||
| Treasury Shares Number | $14,876,316 | $13,634,454 | $4,808,098 | - |
| Ordinary Shares Number | $6,795,779 | $8,037,624 | $16,793,980 | $20,721,047 |
| Share Issued | $21,672,095 | $21,672,078 | $21,602,078 | $20,721,047 |
| Tangible Book Value | $50,341,642 | $26,098,176 | $69,140,917 | $86,370,339 |
| Invested Capital | $51,891,069 | $27,647,603 | $72,690,344 | $89,919,766 |
| Working Capital | $19,460,954 | $43,018,504 | $67,561,036 | $84,790,458 |
| Total Capitalization | $51,891,069 | $39,514,619 | $72,690,344 | $89,919,766 |
| Treasury Stock | $44,607,916 | $42,040,216 | $13,560,623 | $0 |
| Additional Paid In Capital | $181,489,647 | $185,334,173 | $202,230,583 | $201,582,107 |
| Capital Stock | $2,167 | $11,869,183 | $2,160 | $2,072 |
| Common Stock | $2,167 | $2,167 | $2,160 | $2,072 |
| Preferred Stock | $0 | $11,867,016 | $0 | - |
| Non Current Accrued Expenses | $25,000 | $0 | - | - |
| Current Accrued Expenses | $2,489,656 | $395,127 | $400,204 | $499,010 |
| Investments And Advances | $22,474,000 | $0 | $1,572,193 | $1,572,193 |
| Other Short Term Investments | $366,316 | $0 | - | - |
Fetched: 2026-06-18
Cash Flow Statement (Annual)
| Metric | 2025-04-30 | 2024-04-30 | 2023-04-30 | 2022-04-30 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-2,978,296 | $-2,151,457 | $-3,793,731 | $-4,117,319 |
| Operating Activities | ||||
| Operating Cash Flow | $-2,978,296 | $-2,151,457 | $-3,793,731 | $-4,117,319 |
| Cash Flow From Continuing Operating Activities | $-2,978,296 | $-2,151,457 | $-3,793,731 | $-4,117,319 |
| Operating Gains Losses | $-8,171,316 | $-4,174,807 | - | - |
| Investing Activities | ||||
| Investing Cash Flow | $-7,000,000 | $-5,000,000 | $0 | $0 |
| Cash Flow From Continuing Investing Activities | $-7,000,000 | $-5,000,000 | $0 | - |
| Net Other Investing Changes | - | $-5,000,000 | - | - |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-25,029,151 | $-44,358,148 | $-13,560,623 | $0 |
| Issuance Of Capital Stock | $0 | $33,650,075 | $0 | $87,362,049 |
| Financing Cash Flow | $-25,029,151 | $-10,708,003 | $-13,559,743 | $87,311,244 |
| Cash Flow From Continuing Financing Activities | $-25,029,151 | $-10,708,003 | $-13,559,743 | $87,311,244 |
| Net Preferred Stock Issuance | $-22,486,875 | $17,489,544 | $0 | - |
| Preferred Stock Issuance | $0 | $33,650,075 | $0 | - |
| Net Common Stock Issuance | $-2,542,276 | $-28,197,617 | $-13,560,623 | $87,362,049 |
| Common Stock Issuance | - | - | $0 | $87,362,049 |
| Other | ||||
| Income Tax Paid Supplemental Data | $0 | $1,600 | $0 | $509 |
| End Cash Position | $15,172,163 | $50,179,968 | $68,039,936 | $85,400,656 |
| Beginning Cash Position | $50,179,968 | $68,039,936 | $85,400,656 | $2,202,106 |
| Effect Of Exchange Rate Changes | $-358 | $-508 | $-7,246 | $4,625 |
| Changes In Cash | $-35,007,447 | $-17,859,460 | $-17,353,474 | $83,193,925 |
| Proceeds From Stock Option Exercised | $0 | $70 | $880 | $0 |
| Preferred Stock Payments | $-22,486,875 | $-16,160,531 | $0 | - |
| Common Stock Payments | $-2,542,276 | $-28,197,617 | $-13,560,623 | $0 |
| Net Investment Purchase And Sale | $-7,000,000 | $0 | $0 | - |
| Purchase Of Investment | $-7,000,000 | $0 | - | - |
| Change In Working Capital | $1,356,333 | $298,894 | $-297,166 | $9,040 |
| Change In Payables And Accrued Expense | $1,320,292 | $451,013 | $-283,657 | $30,397 |
| Change In Accrued Expense | $1,310,457 | $189,923 | $-40,709 | $-2,703 |
| Change In Payable | $9,835 | $261,090 | $-242,948 | $33,100 |
| Change In Account Payable | $9,835 | $261,090 | $-242,948 | $33,100 |
| Change In Prepaid Assets | $36,041 | $-152,119 | $-13,509 | $-21,041 |
| Other Non Cash Items | $-21,226,734 | $-195,000 | $174,022 | $34,846 |
| Stock Based Compensation | $478,637 | $674,693 | $645,406 | $77,956 |
| Unrealized Gain Loss On Investment Securities | $-6,071,266 | $-1,089,000 | $0 | - |
| Asset Impairment Charge | $0 | $2,000,000 | $0 | - |
| Gain Loss On Investment Securities | $-8,171,316 | $-5,747,000 | - | - |
| Net Income From Continuing Operations | $30,656,050 | $333,763 | $-4,315,993 | $-4,239,161 |
| Repayment Of Debt | - | - | $0 | $-50,805 |
| Interest Paid Supplemental Data | - | - | $0 | $1,600 |
| Net Issuance Payments Of Debt | - | - | $0 | $-50,805 |
| Net Long Term Debt Issuance | - | - | $0 | $-50,805 |
| Long Term Debt Payments | - | - | $0 | $-50,805 |
| Change In Other Current Assets | - | - | $0 | $-316 |
Fetched: 2026-06-18